192 related articles for article (PubMed ID: 36845744)
61. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
[No Abstract] [Full Text] [Related]
62. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
63. A Novel Signature Constructed by RNA-Binding Protein Coding Genes to Improve Overall Survival Prediction of Glioma Patients.
Tu Z; Shu L; Li J; Wu L; Tao C; Ye M; Zhu X; Huang K
Front Cell Dev Biol; 2020; 8():588368. PubMed ID: 33634092
[TBL] [Abstract][Full Text] [Related]
64. TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.
Ugamraj HS; Dang K; Ouisse LH; Buelow B; Chini EN; Castello G; Allison J; Clarke SC; Davison LM; Buelow R; Deng R; Iyer S; Schellenberger U; Manika SN; Bijpuria S; Musnier A; Poupon A; Cuturi MC; van Schooten W; Dalvi P
MAbs; 2022; 14(1):2095949. PubMed ID: 35867844
[TBL] [Abstract][Full Text] [Related]
65. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
Front Genet; 2021; 12():623424. PubMed ID: 33664769
[TBL] [Abstract][Full Text] [Related]
66. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
67. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
68. Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.
Feng S; Liu H; Dong X; Du P; Guo H; Pang Q
Bioengineered; 2021 Dec; 12(2):9692-9708. PubMed ID: 34696669
[TBL] [Abstract][Full Text] [Related]
69. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
Front Oncol; 2021; 11():650153. PubMed ID: 34055619
[TBL] [Abstract][Full Text] [Related]
70. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
71. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
[TBL] [Abstract][Full Text] [Related]
72. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
73. A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.
Cai Y; Liang X; Zhan Z; Zeng Y; Lin J; Xu A; Xue S; Xu W; Chai P; Mao Y; Song Z; Han L; Xiao J; Song Y; Zhang X
Front Cell Dev Biol; 2021; 9():812422. PubMed ID: 35174170
[No Abstract] [Full Text] [Related]
74. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
75. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
76. Construction and validation of a prognostic model based on stage-associated signature genes of head and neck squamous cell carcinoma: a bioinformatics study.
Chen L; Zhang X; Lin J; Wen Y; Chen Y; Chen CB
Ann Transl Med; 2022 Dec; 10(24):1316. PubMed ID: 36660709
[TBL] [Abstract][Full Text] [Related]
77. Prognostic Model and Nomogram Construction and Validation With an Autophagy-Related Gene Signature in Low-Grade Gliomas.
Li X; Huang Z; Zhu L; Yu F; Feng M; Gu A; Jiang J; Wang G; Huang D
Front Genet; 2022; 13():905751. PubMed ID: 35923699
[No Abstract] [Full Text] [Related]
78. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
79. An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas.
Xu Y; Li R; Li X; Dong N; Wu D; Hou L; Yin K; Zhao C
Front Oncol; 2020; 10():571189. PubMed ID: 33194668
[TBL] [Abstract][Full Text] [Related]
80. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
Front Oncol; 2020; 10():1409. PubMed ID: 32974146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
